visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Gut Microbiota-Derived TMAO : |
Data: | 2023 |
Resum: | Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and related complications, such as cardiovascular mortality or major adverse cardiovascular events (MACE). Meta-analyses have postulated that high circulating TMAO levels are associated with an increased risk of cardiovascular events and all-cause mortality, but the link between TMAO and CVD remains not fully consistent. The results of prospective studies vary depending on the target population and the outcome studied, and the adjustment for renal function tends to decrease or reverse the significant association between TMAO and the outcome studied, strongly suggesting that the association is substantially mediated by renal function. Importantly, one Mendelian randomization study did not find a significant association between genetically predicted higher TMAO levels and cardiometabolic disease, but another found a positive causal relationship between TMAO levels and systolic blood pressure, which-at least in part-could explain the link with renal function. The mechanisms by which TMAO can increase this risk are not clearly elucidated, but current evidence indicates that TMAO induces cholesterol metabolism alterations, inflammation, endothelial dysfunction, and platelet activation. Overall, there is no fully conclusive evidence that TMAO is a causal factor of ASCVD, and, especially, whether TMAO induces or just is a marker of hypertension and renal dysfunction requires further study. |
Ajuts: | Instituto de Salud Carlos III PI18-00164 Instituto de Salud Carlos III PI19-00136 Ministerio de Ciencia, Innovación y Universidades PID2019-104367RB-100 Instituto de Salud Carlos III Rio Hortega contract CM20/00033 |
Nota: | Altres ajuts: Red de Investigación en "Enfermedades Metabólicas y Cáncer", RED2018-102799-T ; FPU (Formación de Profesorado Universitario), FPU20/07440 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article de revisió ; recerca ; Versió publicada |
Matèria: | Atherosclerosis ; TMAO ; Mortality ; CVD ; Renal function ; Prospective |
Publicat a: | International journal of molecular sciences, Vol. 24 (january 2023) , ISSN 1422-0067 |
17 p, 942.7 KB |